5 results about "Lipid fraction" patented technology

The invention relates to a composition comprising a cell-free lipoaspirate-derived preparation comprising a lipid fraction and / or an aqueous fraction of a lipoaspirate and at least one biodegradable crosslinked hydrogel. The invention further relates to a device and a kit comprising the composition. The composition, the device and the kit can be generally applied for aesthetic treatment of soft-tissue loss or deficit.

Disclosed is a lipid nanoparticle (LNP) encapsulating a nucleic acid cargo preferably comprising messenger ribonucleic acid (mRNA) The LNP comprises at least a cationic lipid fraction, and a stabilizer fraction. The stabilizer fraction preferably comprises at least one polyethylenglycol (PEG) lipid. Furthermore, the LNP comprises at least one glycerol dialkyl glycerol tetraether (GDGT) lipid, as obtained e.g. from archaea of the genus Sulfolobus, optionally among other ether lipids. Also disclosed is a pharmaceutical composition comprising the LNP, such as an mRNA vaccine.

The invention relates to a composition comprising a cell-free lipoaspirate-derived preparation comprising a lipid fraction and / or an aqueous fraction of a lipoaspirate and at least one biodegradable crosslinked hydrogel. The invention further relates to a device and a kit comprising the composition. The composition, the device and the kit can be generally applied for aesthetic treatment of soft-tissue loss or deficit.

The invention relates to methods for obtaining a fucoxanthin-crystal-containing precipitate, in particular fucoxanthin crystals, in particular fucoxanthin, and a fatty-acid-containing lipid fraction, in particular fatty acids, from the biomass of algae, in particular methods for the integrated extraction and separation of fucoxanthin and fatty acids from the biomass of algae, and to the products obtained from these methods, in particular fucoxanthin crystals and fatty acids.

Disclosed is a lipid nanoparticle (LNP) encapsulating a nucleic acid load, preferably the nucleic acid load comprises a messenger ribonucleic acid (mRNA). The LNP comprises at least an ionizable lipid fraction and a stabilizer fraction. The stabilizer fraction preferably comprises at least one polyethylene glycol (PEG) lipid. In addition, the ionizable lipid fraction comprises at least one ionizable glycerol dialkylglycerol tetraether (GDGT) lipid. Also disclosed is a pharmaceutical composition, such as an mRNA vaccine, comprising the LNP. In further aspects, the invention relates to ionizable GDGT lipids and methods of producing the same.